Tenderskhoj
Germany
- Healthcare & Medical Medical
LOCATION SUMMARY DEADLINE
Germany Conclusion Not Excluding Drug Discount Agreement. According To § 130a Paragraph. 8 Sgb V By Way Of An Openhouse Model For The Active Ingredient Combination Formoterol/glycopyrronium/budesonide (atccode According To Who
 30 Jun 2025
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph. 8/130c Abs. 1 Sgb V On Medicinal Products With The Active Ingredient Ganirelix (h01cc01) Within The Framework Of A So-called Openhouse Model.
 30 Apr 2026
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph. 8/130c Abs. 1 Sgb V On Medicinal Products With The Active Ingredient Estradiol (g03ca03) In The Context Of A So-called Openhouse Model.
 30 Apr 2026
Germany Conclusion Of A Non-exclusive Discount Agreement Pursuant To Section 130a Paragraph 8 Or 130c Paragraph 1 Sgb V For The Period From 01.07.2024 To 30.06.2026
 06 Jun 2024
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130 A Paragraph. 8 Sgb V With The Active Ingredient Tocilizumab
 11 May 2026
Germany Conclusion Of Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph. 8 Sgb V On The Active Ingredient Rituximab
 11 May 2026
Germany Drug Contracts With An Option To Join
 01 May 2026
Germany Conclusion Of Non-exclusive Discount Agreements In Accordance With Section 130a Paragraph. 8/130c Abs. 1 Sgb V On Medicinal Products With The Active Ingredient Follitropin Alfa (g03ga05) Within The Framework Of A So-called Openhouse Model.
 30 Apr 2026
Germany Conclusion Not Excluding Drug Discount Agreement. According To § 130a Paragraph. 8 Sgb V Through An Openhouse Model For The Active Ingredient Aclidinium Bromide (atccode According To Who
 28 Feb 2026
Germany Conclusion Of A Non-exclusive Discount Agreement In Accordance With Section 130a Paragraph. 8 Sgb V On Medicinal Products With The Active Ingredient Pomalidomide (atccode
 27 Apr 2026